[Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation]

Therapie. 2015 Nov-Dec;70(6):485-92. doi: 10.2515/therapie/2015032. Epub 2015 Jul 29.
[Article in French]

Abstract

Objective: Describing the factors associated with direct oral anticoagulants (DOA) prescription in patients with atrial fibrillation (AF).

Method: This study was performed in Toulouse on a cohort of patients received in rhythmology consultation, treated with vitamin K antagonists (VKA) or DOA for AF. A multivariate model was performed using logistic regression to describe the factors associated with DOA prescription and secondly, those associated with discontinuation of the anticoagulant.

Results: Among the 140 patients included, 96 (66%) were treated with VKA and 48 (34%) with DOA. Recent AF diagnosis (OR 7.52, 95% CI [2.41;23.29], p = 0.001), previous exposure to VKA (OR 17.11, 95% CI [4.48;60.91], p<0.001), and no current exposure to anti-platelet agents (APA) (OR 7.69, 95% CI [1.22; 50.00], p = 0.030) were associated to DOA prescription. Discontinuation of the anticoagulant (n=24) was associated to DOA intake (OR 2.71, 95% CI [1.21; 6.08], p = 0.016).

Discussion: DOA are less prescribed than VKA in patients treated with APA. DOA switch to VKA was not systematic in patients diagnosed for a long time. However, international normalized ratio (INR) values were stable in most of patients treated with VKA at the switching to DOA. A more powerful study would confirm the factors associated with DOA prescription.

Publication types

  • Comparative Study
  • English Abstract
  • Observational Study

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Anticoagulants / classification
  • Anticoagulants / therapeutic use*
  • Antithrombins / administration & dosage
  • Antithrombins / adverse effects
  • Antithrombins / therapeutic use*
  • Atrial Fibrillation / complications*
  • Comorbidity
  • Dabigatran / administration & dosage
  • Dabigatran / adverse effects
  • Dabigatran / therapeutic use
  • Drug Substitution
  • Factor Xa Inhibitors / administration & dosage
  • Factor Xa Inhibitors / adverse effects
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Hemorrhage / chemically induced
  • Hemorrhage / epidemiology
  • Humans
  • Intracranial Embolism / epidemiology
  • Intracranial Embolism / etiology
  • Intracranial Embolism / prevention & control*
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use
  • Practice Patterns, Physicians'
  • Prospective Studies
  • Pyrazoles / administration & dosage
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use
  • Pyridones / administration & dosage
  • Pyridones / adverse effects
  • Pyridones / therapeutic use
  • Rivaroxaban / administration & dosage
  • Rivaroxaban / adverse effects
  • Rivaroxaban / therapeutic use
  • Thrombophilia / drug therapy*
  • Thrombophilia / etiology
  • Vitamin K / antagonists & inhibitors*
  • Warfarin / administration & dosage
  • Warfarin / adverse effects
  • Warfarin / therapeutic use

Substances

  • Anticoagulants
  • Antithrombins
  • Factor Xa Inhibitors
  • Platelet Aggregation Inhibitors
  • Pyrazoles
  • Pyridones
  • Vitamin K
  • apixaban
  • Warfarin
  • Rivaroxaban
  • Dabigatran